ANI Pharmaceuticals Inc (ANIP NASDAQ) stock market data APIs
$83.7225
0.65(0.8%)
as of May 7, 2026
Try our APIs with
free plan!
ANI Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Prev. Close
83.7225
Open
84.3678
High
85.1385
Low
82.178
52 wk Range
56.71-99.5
Market Cap
1 909 M
P/E Ratio
25.2741
Shares Outstanding
22 750 K
Revenue
883 M
EPS
2.33
Beta
0.455
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ANI Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ANI Pharmaceuticals Inc data using free add-ons & libraries
Get ANI Pharmaceuticals Inc Fundamental Data
ANI Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 883 M
- EBITDA: 175 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: 2.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ANI Pharmaceuticals Inc News
New
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $237.5 million. The company’s full-year re...
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals, Inc. Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year Purified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year Qu...
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago. Thes...
Cheniere Energy to Report Q1 Earnings: What's in the Offing?
Cheniere Energy, Inc. LNG is set to release first-quarter 2026 results on May 7.The Zacks Consensus Estimate for earnings is pegged at $3.91 per share on revenues of $5.7 billion. Let us delve into t...
Get ANI Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
